May 26, 2021

Single-Dose SARS-CoV-2 Vaccine in a Prospective Cohort of COVID-19 Patients

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): antibodies, immunity, vaccine, variant

• [Pre-print, not peer-reviewed] A study comparing antibody responses in 155 previously SARS-CoV-2 infected individuals found a single dose of the Pfizer-BioNTech vaccine provided neutralizing antibody titers exceeding those produced following two vaccine doses in 49 previously uninfected healthcare workers. Additionally, pre-vaccination neutralization titers in persons with previous infection were associated with higher neutralization titers after vaccination, independent of disease severity or time since infection up to 15 months after SARS-CoV-2 infection. Serum samples from a random selection of 20 participants with previous infection and one dose also demonstrated cross-neutralization of variants B.1.351, P.1, and B.1.1.7.  The authors suggest these findings support implementation of a single-dose mRNA vaccine strategy in persons with prior SARS-CoV-2 infection.

Gils et al. (May 25, 2021). Single-Dose SARS-CoV-2 Vaccine in a Prospective Cohort of COVID-19 Patients. Pre-print downloaded May 26 from https://doi.org/10.1101/2021.05.25.21257797